Increase expression of ABCA1 at protein level after LXR agonist treatment was confirmed by induction of ABCA1 expression on PDC membrane, as assessed by confocal microscopy ( Figure 1B ).
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The Anti-Inflammatory Effects of Platelet-Derived Microparticles in Human Plasmacytoid Dendritic Cells Involve Liver X Receptor Activation
Adam Ceroi, [1] [2] [3] [4] Fanny Angelot Delettre, [1] [2] [3] [4] Charline Marotel, [1] [2] [3] Thierry Gauthier, [1] [2] [3] [4] Afag Asgarova, [1] [2] [3] Sabéha Biichlé, [1] [2] [3] [4] Anne Duperrier, [1] [2] [3] Guillaume Mourey, [1] [2] [3] Sylvain Perruche, [1] [2] [3] [4] Laurent Lagrost, [4] [5] [6] [7] David Masson, [4] [5] [6] [7] and Philippe Saas product internalization, such as apoptotic bodies 9 that belong together with MP to extracellular vesicles. Here, implication of the LXR pathway in MP engulfment by PDC and the subsequent PDC inflammatory responses were investigated. Freshly isolated PDC were treated with either LXR agonists (T0901317, GW3965, 22RHC) or LXR antagonist (22SHC) for 24 hours, and expression of LXR target genes (srebp1c and abca1) was assessed by qRT-PCR. 22SHC inhibited srebp1c mRNA expression, while LXR agonists increased both srepb1c and abca1 mRNA ( Figure 1A ), suggesting LXR pathway activation in PDC. LXR (lxra and lxrb) isoform mRNA expression was assessed by qRT-PCR in freshly isolated PDC. Preferential expression of the ubiquitous lxrb isoform mRNA by PDC was shown (Supplemental Figure 1 ).
Increase expression of ABCA1 at protein level after LXR agonist treatment was confirmed by induction of ABCA1 expression on PDC membrane, as assessed by confocal microscopy ( Figure 1B ).
In other immune cells, LXR activation has been described to alter TLR stimulation, 8, 10 and promote phosphatidylserine (PtdSer) positive apoptotic body internalization. 9 We evaluated whether LXR stimulation modulates PDC responses to TLR signaling. PDC were first treated with LXR agonists for 24 hours, and stimulated with TLR ligands, R848 (TLR7) and CpG-ODN2216 (TLR9) for 18 hours.
Secretion of TNF-α and IL-6 was significantly reduced when PDC were pretreated with LXR agonists ( Figure 1C ). PDC CAL-1 cells expressed reduced intracellular TNF-α levels when pretreated with LXR agonists before TLR7 stimulation ( Figure 1C ). However, LXR agonist pretreatment did not affect TLR9-induced cytokine production by PDC ( Figure 1C ). In contrast to TLR9, TLR7 stimulation involves predominantly the canonical NF-κB signaling pathway in PDC. 11 Pretreatment of PDC for 24 hours with LXR agonists, T0901317 or GW3965 followed by R848 stimulation for 45 minutes decreased significantly pRelA staining analyzed by confocal microscopy ( Figure 1D ). This demonstrates that the LXR pathway is fully functional in human PDC and its activation inhibits TLR7-mediated NF-κB activation and pro-inflammatory cytokine secretion. This was shown using three different LXR agonists, including GW3965 considered as a pure LXRα/β agonist. 12 As described in macrophages or conventional DC, 8, 10 LXR triggering in PDC blocks TLR signaling pathway. NF-κB inhibition by LXR triggering involves stabilization of a corepressor/NF-κB complex in target gene promoter, 8 or prevention of NF-κB p50 subunit nuclear translocation. 10 Here, we observed an inhibition of RelA phosphorylation.
Despite PDC are not professional phagocytes participating to apoptotic cell/body removal like macrophages (discussed in Ref. 13 ), PDC are able to internalize membrane-derived MP. 5 We then evaluated the role of LXR in PtdSer-dependent MP internalization by PDC. After showing that MP uptake by PDC was PtdSer-dependent using AnxV, we observed that LXR stimulation significantly increased eFluor-labeled MP internalization by PDC ( Figure 1E ). T0901317 treatment showed a concentration-dependent upregulation of bai1 mRNA levels. The same effect was obtained with the 4 two other LXR agonists, while 22SHC did not change bai1 mRNA expression ( Figure 1F ). Increased BAI-1 membrane expression on PDC was confirmed after T0901317 or GW3965 treatment by cytometry ( Figure 1G ). Finally, blockade of BAI-1 using an anti-BAI-1 antibody significantly reduced MP uptake by LXR-stimulated PDC ( Figure 1H ). While LXR activation in macrophages induces Mer-tk expression, 9 neither stabilin2, tim1, tim4 nor mertk PtdSer receptor mRNA expression were modulated in PDC after LXR activation (data not shown). Moreover, Mer-tk blockade in PDC has no effect (data not shown). Overall, LXR activation in PDC significantly enhances MP uptake through upregulation of the Ptdser receptor BAI-1. This was observed whatever the MP origin, EMP or PMP (Supplemental Figure 2 ).
Since MP contain potential cholesterol-derived LXR ligands, 6 we evaluated LXR activation in PDC after MP co-culture. PMP or EMP were previously reported to exert anti-or pro-inflammatory effects, respectively. 5 We confirmed here that PMP decreased TNF-α and IL-8 secretion in a PMP numberdependent manner (Figure 2A -B). Looking at the LXR pathway, we observed a significant induction of LXR target gene (lxra, srebp-1c and abca1) and bai1 transcription, while tnfa mRNA levels were significantly diminished in PDC depending again on the number of PMP ( Figure 2C ). PDC pretreatment with the LXR antagonist 22SHC before PMP addition tend to prevent LXR target gene expression upregulation while increased significantly tnfa mRNA expression ( Figure 2D ). This identifies a novel anti-inflammatory mechanism of PMP: the activation of LXR pathway.
EMP are endowed with pro-inflammatory properties. 5 After having confirmed that TNF-α and IL-8 secretion were increased after EMP incubation, we observed that EMP induced NF-κB activation in PDC associated with an increase of tnfa mRNA levels ( Figure 3A) . A downregulation of LXR target gene (srebp1c and abca1) transcription in PDC in an EMP number-dependent manner was also observed ( Figure 3B ). This effect of EMP was prevented by the prior LXR activation and associated with a significant decreased tnfa mRNA expression ( Figure 3C ). These data suggest an inhibition of LXR pathway by NF-κB. To confirm this hypothesis, PDC CAL-1 cells were treated simultaneously with the LXR agonist GW3965 and TLR7 ligand R848 in the presence of the NF-κB inhibitor, JSH-23
or not. R848 treatment downregulated LXR target gene expression induced by GW3965, while JSH-23 addition reversed totally this effect ( Figure 3D ). Thus, TLR signaling pathway dominates LXR pathway and NF-κB blockade is sufficient to restore LXR pathway activation. To translate this observation into EMP, freshly isolated PDC co-cultured with EMP were simultaneously treated with JSH-23. While JSH-23 restored slightly the increase of lxra mRNA expression, we observed a reduction of il6 and tnfa mRNA levels, statistically significant for tnfa mRNA ( Figure 3E ). Restoration of LXR pathway activation in response to EMP by NF-κB blockade was confirmed by increased ABCA1 membrane expression, assessed by confocal microscopy ( Figure 3F ). Finally, PDC treatment 5 with R848 simultaneously to PMP decreased significantly lxra mRNA expression induced by PMP and increased il6 mRNA expression (Supplemental Figure 3) . These results confirm the critical role of NF- Platelet-derived microparticles (PMP) were isolated from platelet concentrates (EFS B/FC) obtained from healthy donors after written informed consent. Platelets were removed by two centrifugations at 2500g 15 min at room temperature (RT). Supernatants were collected and ultracentrifuged twice (15000g, 90 min, 4°C) to isolate PMP that were used or stored in same conditions than EMP. 2 Quantification of MP was performed by flow cytometry using a Navios cytometer (Beckman Coulter, Villepinte, France), Megamix plus™ (BioCytex, Marseille, France) to assess MP size and MP number was calculated on the basis of the known number of Cytocount® beads (Dako, Trappes, France) added to the sample. Identification of MP was performed after staining with fluorochrome-conjugated mAbs (Supplemental Table  1 ). Expression of phosphatidylserine by MP was assessed by cytometry using FITCconjugated Annexin-V (AnxV, Beckmann Coulter).
Evaluation of plasmacytoid dendritic cell responses. Functional expression of LXR by human PDC was assessed by using both LXR agonists (T0901317, GW3965 3 or 22RHC [22-R-hydroxycholesterol]) or antagonist (22-S-hydroxycholesterol, 22SHC 4 ) (Sigma Aldrich) and then, by analyzing induction of LXR target genes (see below) or expression of LXR (lxra and lxrb) isoform mRNA, assessed by qRT-PCR ( Figure S1 ). ABCA-1 protein expression was assessed by confocal microscopy. Concentrations of LXR agonists or antagonist used were defined to avoid PDC death as assessed by AnxV and 7-Aminoactinomycin D (7-AAD, BD Bioscience) staining and flow cytometry. To assess the effects of LXR activation on innate PDC functions, freshly isolated PDC were stimulated with LXR agonist/antagonist for 24 h, and then, by either Toll-like receptor (TLR)7 ligand R848 (1 µg/ml, Invivogen, Toulouse, France), or TLR9 ligands, CpG-A (2 µmol/L, ODN2216, Invivogen) for additional 6 h (for mRNA analysis) or 18 h for (protein analysis). To assess the effects of MP on PDC functions, EMP or PMP were added to PDC at different PDC to MP ratio (1:10, 1:40, 1:80) for 18 hours. Maturation of PDC was assessed by expression of maturation marker CD83 or costimulatory molecules by cytometry and cytokine production (at protein levels by ELISA, multiplex assay or intracellular staining/cytometry and at mRNA levels by transcript quantification). Internalization of MP by PDC was also assessed using labeled-MP (see below). Prevention of NF-kB activation in PDC was performed using JSH-23 (25 µM, Sigma Aldrich), a NF-kB p65 nuclear translocation inhibitor.
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Flow cytometry and antibodies. For PDC analysis, flow cytometry was performed with a CANTO II cytometer (BD Biosciences, Le Pont de Claix, France) using the DIVA 6.1 software (BD Biosciences). Fluorochrome-conjugated isotype control mAbs from the different mAb providers were used. Monoclonal antibodies used for cytometry and other cytometry reagents are described in supplemental table 1.
Cytokine production. Culture supernatants were collected from PDC after LXR ligand stimulation (24 h) followed or not by TLR ligand (18 h), or after stimulation by EMP or PMP (18 h). The multiplex DIAplex technology (Diaclone, Besançon, France) was used to measure the following cytokines: TNF-α, IL-10, IL-6 and IL-8. The human IFN-alpha Platinum ELISA kit (eBioscience SA, Paris, France) was used to measure IFN-α. The minimal detectable concentrations were as follows: 1.7 pg/mL, 1.3 pg/mL, 1.4 pg/mL, 9.8 pg/mL and 15 pg/ml for IL-10, IL-8, IL-6, TNF and IFN-α, respectively. Production of IFN-α, IL-6 and TNF-α by PDC was also determined by flow cytometry and intracellular staining using anti-IFN-α, anti-IL-6 and anti-TNF-α mAb, respectively (Supplemental Table 1 ). Brefeldin A (10 µg/ml, Sigma Aldrich) was added during the last 3 h before the end of activation with TLR ligands or MP. Staining was performed according to the manufacturer's instructions on fixed and permeabilized cells (cytofix/cytoperm Plus kit, BD Biosciences).
Microparticle internalization. Microparticle uptake was assessed by cytometry, as described. 2 Microparticles (EMP or PMP) were labeled with either CellTrace™ CFSE Cell Proliferation Kit (Thermo Scientific™, Fontenay-sous-Bois, France) or eFluor proliferation dye v450 (eBioscience) according to the manufacturers' instructions, and then, incubated at different ratio (see above) with freshly isolated PDC. Internalization was blocked before labeled-MP addition by pre-incubation (30 minutes) of MP with unlabeled AnxV (BD Biosciences), or PDC pre-incubation (1 hour) with either anti-BAI-1 mAb or anti-Mer-TK polyclonal antibody (R&D Systems, Lille, France), control isotype irrelevant mAb or polyclonal antibody (R&D Systems). Effects of LXR agonists on MP internalization were assessed by incubating PDC, with either T0901317 or GW3965 24 h prior addition of labeled-MP.
Quantitative RT-PCR analysis. Quantitative RT-PCR analysis was used to evaluate functionally LXR expression by measuring LXR-target gene expression (i.e., lxra, abca1 and srebp1c) and confirm the effects of LXR agonists or MP on LXR target gene, endocytosis receptor or cytokine gene expression. Total RNA was extracted using RNeasy Mini Kit (Qiagen, Courtaboeuf, France). One to 2 µg of RNA was reverse-transcribed into cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems, Saint Aubin, France). Then, cDNA were quantified by real time RT-PCR using either the Power SYBR Green PCR Master Mix (Applied Biosystems) or the Taqman Universal Buffer II (Applied Biosystems) on a CFX96 Real-Time device (Biorad, Marnes-la-Coquette, France). Relative mRNA levels were determined using the ∆∆Ct method. Values were expressed relative to gapdh levels. The sequences of the oligonucleotides used are described in supplemental table 2.
Confocal microscopy. CAL-1 cells or freshly isolated PDC were incubated with LXR agonist for 24 h before CD123 and ABCA1 analysis. Phosphorylated NF-κB p65 (pRelA) analysis was performed after LXR treatment of PDC followed by R848 stimulation for 45 min. PDC stimulated with MP were directly stained for ABCA1 or pRelA. Cells were collected in cold PBS solution, washed and Figure S1 . Freshly isolated plasmacytoid dendritic cells express preferentially the ubiquitous isoform lxrb mRNA.
Supplemental Figures
Lxra and lxrb mRNA levels were evaluated in freshly isolated untreated PDC by qRT-PCR. The mRNA relative levels of PDC samples (n=24 and n=5 for lxra and lxrb, respectively) were compared to the mean of HepG2 hepatoma cell line (a control for lxra), PBMC or CAL-1 PDC cell line (n=4, n=4 and n=12, respectively). PDC express lower levels of lxra mRNA than HepG2 and similar levels of lxr isoforms than PBMC and CAL-1 cells. PDC were treated with 1 µM of T0901317 (T09) or GW3965 (GW) for 24 hours. Then, cells were cultured for 1 hour with neutralizing anti-BAI-1 antibody (α-BAI-1) or control antibody, before adding eFluor-labeled EMP or PMP for 4 h and analyzing by cytometry. (n=4 and 2 for EMP and PMP respectively). Cumulative data of 4 or 2 independent experiments expressed as mean + S.E.M. of eFluor + PDC are shown. * p<0.05, ** p<0.01, Mann-Whitney
